Suzetrigine (JOURNAVX) Criteria for Use MAY 2025 VA Pharmacy Benefits Management Services and National Formulary Committee The following recommendations are based on …

JOURNAVX EHR Guide - Oracle Health An instructional guide that provides steps and criteria to update the EHR to include JOURNAVX, support healthcare providers (HCPs) and their …

Feb 5, 2025 · s, all emphasized multimodality management of pain. Such management was seen as limiting the need for opioid medication and potentially lo ering the risk of patients …

Jun 5, 2025 · Journavx, a new non-opioid medication recently approved by the FDA, shows promise as a potential treatment for acute pain following surgery.

Journavx (jor-na-vix) was approved in 2025 and is the first non-opioid medicine in its class that is used to treat moderate to severe acute pain. How Does It Work for Pain?

Feb 2, 2025 · To further facilitate the adoption of Journavx, training programs for emergency staff are essential, equipping them with the knowledge and skills needed to effectively incorporate …

Apr 25, 2025 · Explore our review of ICER’s Final Report on suzetrigine (Journavx®) for acute pain. Learn how this non-opioid therapy’s clinical value, pricing, and potential to curb opioid …

May 28, 2025 · Pain medicine specialists provide perspective on survey results regarding suzetrigine’s potential use, drug interactions, and what remains unknown.

The safety of Journavx was based on pooled data from the two phase 3 trials that included 874 adult patients with moderate to severe acute pain following full abdominoplasty (Trial 1) and ...

These programs track prescriptions in real time, flagging any unusual patterns that may indicate misuse. Hospital and Clinical Compliance Hospitals and healthcare facilities must integrate …